Exhibit 10.2
AMENDMENT TO CONSULTING AGREEMENT
Effective March 11, 2003 (the “Effective Date”), Hollis-Eden Pharmaceuticals, Inc. , a Delaware corporation (the
“Company”), William H. Tilley (“Tilley”) and JacMar/Viking, L.L.C. , a Delaware limited liability company (“Consultant”),
agree as follows:
RECITALS
WHEREAS, the Company, Tilley and Consultant are parties to that certain Consulting Agreement made effective March 8,
1999, as amended on March 12, 2001 (the “Agreement”); and
WHEREAS, the parties desire to amend certain provisions of the Agreement.
NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties agree to amend and hereby do amend the Agreement as follows:
AMENDMENT
1.
Each defined term used herein shall have the same meaning as set forth in the Agreement.
2.
Section 1.3 is amended to read in its entirety:
“ 1.3 Term. Unless sooner terminated as provided in Section 1.5 hereof, this Agreement has become effective as of
the date set forth above and shall continue in force and effect until March 11, 2006.”
3.
Subsection 1.5(b) is amended to read in its entirety:
“ (b) Termination by Company or Consultant. In the event that, during the term hereof, the Company or Consultant
terminates this Agreement, for any reason or for no reason, or Tilley or Consultant shall refuse to perform the services
required hereunder, then, in such event, this Agreement shall automatically be terminated and Consultant shall have
the right to receive any unpaid compensation or reimbursements to the date of termination, but no other
compensation.”
IN WITNESS WHEREOF, the parties have signed this Amendment or caused an authorized officer to sign this Amendment
to be effective on the Effective Date.
AMENDMENT TO WARRANT NO. W-99-5
TO PURCHASE 250,000 SHARES OF COMMON STOCK
OF HOLLIS-EDEN PHARMACEUTICALS, INC.
Effective March 11, 2003 (the “Effective